Search This Blog

Tuesday, December 8, 2015

Amgen's First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501

Supported By Phase 3 Studies in Moderate-to-Severe Plaque Psoriasis and Moderate-to-Severe Rheumatoid Arthritis



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.